baclofen has been researched along with Central Nervous System Diseases in 11 studies
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 7.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
| "We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 3.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
| " They also required higher doses and more rapid dosage increases." | 2.68 | Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. ( Dressnandt, J; Marquardt, G; Mauch, E; Meinck, HM; Müller-Schwefe, G; Rieke, K; Schumm, F; Stayer, C; Tronnier, V, 1997) |
| "Baclofen is a centrally-acting γ-amino butyric acid agonist used mainly in the symptomatic management of spasticity originating from the spinal cord." | 2.58 | Baclofen-induced neurotoxicity in patients with compromised renal function: Review. ( Achanti, A; Arany, I; Beck Gööz, M; Castaneda, J; Dreisbach, AW; Fülöp, T; Salim, SA; Thomas, L, 2018) |
| "To report the toxic effects of baclofen in patients with severely impaired renal function." | 2.40 | Baclofen toxicity in patients with severely impaired renal function. ( Bullard, MJ; Chen, KS; Chien, YY; Lee, SY, 1997) |
| "We studied the effects of GABA on anoxia-induced injury in CNS white matter using optic nerves exposed to 60 min of anoxia." | 1.29 | Endogenous GABA attenuates CNS white matter dysfunction following anoxia. ( Fern, R; Ransom, BR; Waxman, SG, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salim, SA | 1 |
| Thomas, L | 1 |
| Achanti, A | 1 |
| Beck Gööz, M | 1 |
| Castaneda, J | 1 |
| Arany, I | 1 |
| Dreisbach, AW | 1 |
| Fülöp, T | 1 |
| Taira, T | 1 |
| Grabow, TS | 1 |
| Christo, PJ | 1 |
| Raja, SN | 1 |
| Kerr, DI | 1 |
| Ong, J | 1 |
| Fern, R | 1 |
| Waxman, SG | 1 |
| Ransom, BR | 1 |
| Chen, KS | 1 |
| Bullard, MJ | 1 |
| Chien, YY | 1 |
| Lee, SY | 1 |
| Stayer, C | 1 |
| Tronnier, V | 1 |
| Dressnandt, J | 1 |
| Mauch, E | 1 |
| Marquardt, G | 1 |
| Rieke, K | 1 |
| Müller-Schwefe, G | 1 |
| Schumm, F | 1 |
| Meinck, HM | 1 |
| Leroy-Malherbe, V | 1 |
| Laurent-Vannier, A | 1 |
| Brugel, DG | 1 |
| Urtizberea, JA | 1 |
| Gatscher, S | 1 |
| Becker, R | 1 |
| Uhle, E | 1 |
| Bertalanffy, H | 1 |
| Halbhübner, K | 1 |
| Herken, H | 1 |
| Loos, D | 1 |
| Young, RR | 1 |
5 reviews available for baclofen and Central Nervous System Diseases
| Article | Year |
|---|---|
Baclofen-induced neurotoxicity in patients with compromised renal function: Review.
Topics: Baclofen; Central Nervous System Diseases; Humans; Muscle Relaxants, Central; Renal Insufficiency | 2018 |
Complex regional pain syndrome: diagnostic controversies, psychological dysfunction, and emerging concepts.
Topics: Autonomic Nervous System Diseases; Baclofen; Caregivers; Central Nervous System Diseases; Combined M | 2004 |
GABAB receptors.
Topics: Baclofen; Binding, Competitive; Cations, Divalent; Central Nervous System; Central Nervous System Di | 1995 |
Baclofen toxicity in patients with severely impaired renal function.
Topics: Adult; Aged; Baclofen; Central Nervous System Diseases; Contraindications; Female; Humans; Kidney Fa | 1997 |
[Recent progress in pediatric neurological rehabilitation].
Topics: Adolescent; Adult; Age Factors; Animals; Baclofen; Botulinum Toxins; Central Nervous System Diseases | 2002 |
1 trial available for baclofen and Central Nervous System Diseases
| Article | Year |
|---|---|
Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus.
Topics: Adult; Aged; Baclofen; Central Nervous System Diseases; Cohort Studies; Disease Progression; Female; | 1997 |
5 other studies available for baclofen and Central Nervous System Diseases
| Article | Year |
|---|---|
[Intrathecal baclofen therapy].
Topics: Baclofen; Central Nervous System Diseases; GABA-B Receptor Agonists; Humans; Infusion Pumps, Implant | 2010 |
Endogenous GABA attenuates CNS white matter dysfunction following anoxia.
Topics: Animals; Axons; Baclofen; Central Nervous System Diseases; Enzyme Activation; Female; gamma-Aminobut | 1995 |
Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain.
Topics: Afferent Pathways; Analgesics, Opioid; Baclofen; Central Nervous System Diseases; Denervation; Drug | 2002 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; | 1978 |
The physiology of spasticity and its response to therapy.
Topics: Animals; Baclofen; Central Nervous System Diseases; Dantrolene; Diazepam; Humans; Motor Neurons; Mus | 1988 |